Every 424B that TEVOGEN INC (TVGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TVGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TVGN filings page.
Tevogen Bio Holdings Inc. registers up to 375,000 shares of common stock for resale by a selling stockholder. This prospectus covers resale, from time to time, by the identified Selling Stockholder of up to 375,000 shares issuable upon exercise of Pre-Funded Warrants issued in May 2026. The company is not selling any shares hereunder and will receive no proceeds from resale; the issuer will receive the net proceeds only if the Pre-Funded Warrants are exercised for cash, which have an aggregate exercise price of $37.50. The prospectus notes a Beneficial Ownership Limitation of 9.99% (adjustable to 19.99% with notice), and states 4,219,343 shares outstanding as of June 11, 2026.
Tevogen Bio Holdings Inc. filed a prospectus supplement dated March 25, 2026 that attaches a Form 8-K reporting the company has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5450(a)(1).
The Nasdaq notice followed the implementation of a 1-for-50 reverse stock split that became effective on March 6, 2026. The supplement references the Prospectus dated May 7, 2025 and shows closing prices on March 24, 2026 of $5.22 for Common Stock and $0.0346 for Warrants.
Tevogen Bio Holdings Inc. effected a 1-for-50 reverse stock split of its common stock, effective March 6, 2026. The Company reported 202,416,556 shares issued and outstanding as of March 3, 2026 that will be combined at the 1-for-50 ratio.
The Common Stock will trade on Nasdaq on a split-adjusted basis under the same symbol, and the Company issued a new CUSIP, 88165K200. Fractional shares will not be issued; holders entitled to fractional shares will receive cash in lieu based on the closing trading price on the trading day immediately preceding the Effective Date. Convertible preferred shares, warrants and equity awards will be adjusted by dividing share counts by 50 and multiplying per-share conversion/exercise prices by 50.
Tevogen Bio Holdings Inc. updated its prospectus supplement to report stockholder approvals from a February 19, 2026 special meeting. Shareholders approved an amendment adding 100,000,000 shares to the 2024 Omnibus Incentive Plan and approved a reverse stock split between 1:25 and 1:85, with the exact ratio and timing to be determined by the Board in its sole discretion.
The filing states there were 201,522,282 shares of Common Stock issued and outstanding as of January 21, 2026. Vote tallies show strong support for both proposals; the Plan Amendment received 147,777,455 votes for and the Reverse Stock Split Proposal received 176,344,447 votes for.
Tevogen Bio Holdings Inc. filed a Rule 424(b)(3) prospectus supplement to update its S‑1 with the attached Quarterly Report for the period ended September 30, 2025. The company remains a clinical‑stage developer of off‑the‑shelf precision T cell therapies and reports no product revenue.
For Q3 2025, Tevogen reported a net loss of $5,726,812 and a nine‑month net loss of $21,597,852. Cash was $1,037,094 at September 30, 2025. Management cites liquidity sources including a $50,000,000 at‑the‑market Sales Agreement entered July 3, 2025, with net proceeds of $3.101,409 through Q3 and $3.9 million through November 12, 2025; an unsecured related‑party Loan Agreement with $4,400,000 outstanding and $21,000,000 remaining capacity; and KRHP grants of $3.0 million year‑to‑date with an additional $7.0 million committed. The company states it has adequate resources for at least the next 12 months and does not plan to initiate a clinical trial until additional funding is received.
Common shares outstanding were 197,391,411 as of September 30, 2025, and 198,689,921 as of November 12, 2025. Nasdaq closing prices on November 13, 2025 were $0.4443 for TVGN and $0.0474 for TVGNW.